AnaptysBio Stock

AnaptysBio EBIT

The EBIT of AnaptysBio (ANAB) as of Jul 19, 2026 is 47.90 M USD. In the previous year, EBIT was -114.95 M USD — a change of -141.67% (higher).

EBIT

47.90 MUSD

YoY

-141.67%

Last updated:

In 2026, AnaptysBio's EBIT was 47.90 M USD, a -141.67% increase from the -114.95 M USD EBIT recorded in the previous year.

The AnaptysBio EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-114.95 base
Jan 1, 2025
47.90 base
Jan 1, 2026 (e)
-84.51 base
Jan 1, 2027 (e)
-129.86 base
Jan 1, 2028 (e)
-55.23 base
Jan 1, 2029 (e)
-77.50 base
Jan 1, 2030 (e)
103.17 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 103.17
2029 est -77.50
2028 est -55.23
2027 est -129.86
2026 est -84.51
2025 47.90
2024 -114.95
2023 -157.07
2022 -115.15
2021 -56.81
2020 -23.88
2019 -107.43
2018 -66.72
2017 -28.78
2016 -3.03
2015 -3.32
2014 4.87
2013 -5.29
Access this data via the Eulerpool API

AnaptysBio Revenue

AnaptysBio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
91.28 M USD
-114.95 M USD
-145.23 M USD
Jan 1, 2025
234.60 M USD
47.90 M USD
-13.23 M USD
Jan 1, 2026 (e)
139.32 M USD
-84.51 M USD
-134.17 M USD
Jan 1, 2027 (e)
185.98 M USD
-129.86 M USD
-158.12 M USD
Jan 1, 2028 (e)
263.11 M USD
-55.23 M USD
-91.59 M USD
Jan 1, 2029 (e)
326.32 M USD
-77.50 M USD
-52.51 M USD
Jan 1, 2030 (e)
499.22 M USD
103.17 M USD
110.88 M USD
Jan 1, 2031 (e)
709.19 M USD
0.00 USD
221.17 M USD

AnaptysBio Margins

AnaptysBio stock margins

The AnaptysBio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AnaptysBio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AnaptysBio.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
0.00 %
-125.93 %
-159.10 %
Jan 1, 2025
0.00 %
20.42 %
-5.64 %
Jan 1, 2026 (e)
0.00 %
-60.66 %
-96.31 %
Jan 1, 2027 (e)
0.00 %
-69.82 %
-85.02 %
Jan 1, 2028 (e)
0.00 %
-20.99 %
-34.81 %
Jan 1, 2029 (e)
0.00 %
-23.75 %
-16.09 %
Jan 1, 2030 (e)
0.00 %
20.67 %
22.21 %
Jan 1, 2031 (e)
0.00 %
0.00 %
31.19 %

AnaptysBio Stock analysis

What does AnaptysBio do? AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing AnaptysBio's EBIT

AnaptysBio's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of AnaptysBio's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

AnaptysBio's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in AnaptysBio’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about AnaptysBio stock

EBIT of AnaptysBio is 47.90 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — AnaptysBio

All Key Metrics — AnaptysBio